{"entity":{"id":"nct07134101","kind":"trial","name":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","aka":["SMARTi-RC01"],"tldr":"A phase 2 trial of serplulimab and bevacizumab (glioblastoma use) in colorectal cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","summary":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) is a phase 2, randomised interventional study registered as NCT07134101 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 138 participants, started 2025-09-01 and due to reach its primary completion in 2028-08-31. Interventions recorded: Serplulimab; Bevacizumab; Short-Course Radioterapy; Chemotherapy (CAPOX or capecitabine). Conditions listed: Colorectal Cancer (Diagnosis). Primary outcome: Complete Remission (CR) Rate assessed by pathology, MRI, endoscopy, and clinical examination. Colorectal eligibility wording from the registry: \"Diagnosis: Pathologically confirmed rectal adenocarcinoma with proficient mismatch repair (pMMR) / microsatellite stable (MSS) status, based on biopsy of the primary tumor\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07134101","url":"https://clinicaltrials.gov/study/NCT07134101"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["serplulimab","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07134101","phase":"2","setting":"Neoadjuvant Chemoradiotherapy Combined With Serplulimab With or Without Bevacizumab for Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Phase II Randomized Trial","sponsor":"The First Affiliated Hospital with Nanjing Medical University","enrolled":138,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07134101/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}